Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining b-cell function and the achievement of the HbA1c target 1 year after initiation
1
for their interest and comments on our recent article regarding the glycated hemoglobin (HbA1c)-lowering effect of glucagon-like peptide-1 receptor agonist liraglutide with basal insulin among Japanese individuals with type 2 diabetes.
We have reported that the HbA1c-lowering effects of liraglutide/basal insulin combination rely on remaining b-cell function, and that the cut-off value of the C-peptide immunoreactivity index, a b-cell function-related index frequently used in Japanese clinical settings, is 1.103 for the achievement of HbA1c < 7.0% at 54 weeks after initiating the liraglutide/ basal insulin combination 2 . In our study, we found that changes in HbA1c were not affected by type 2 diabetes duration, unlike the Wilbrink et al. study (Figure 1b) . This discrepancy might be due to several reasons. First, we studied patients receiving liraglutide/basal insulin combination in replacement of multiple daily injection insulin therapy or basal insulin-supported oral therapy, whereas Wilbrink et al. studied those receiving liraglutide in replacement of insulin therapy. We previously showed that discontinuation of liraglutide as a result of hyperglycemia after switching from insulin is affected by remaining b-cell function and type 2 diabetes duration 3 . In addition, we also reported that the HbA1c-lowering effects of liraglutide monotherapy and sulfonylurea combination rely on remaining b-cell function and type 2 diabetes duration ( Figure 1a ) in a study in which 74% of the study patients had been taking insulin before initiating liraglutide 4 . Importantly, the Cpeptide immunoreactivity index cut-off value for HbA1c < 7.0% achievement by liraglutide monotherapy and sulfonylurea combination was higher than that of liraglutide/basal combination (1.86 and 1.10, respectively) 2, 4 . It is widely accepted that b-cell function progressively declines over time in type 2 diabetes patients, making it difficult to obtain appropriate glycemic control without insulin use 5, 6 . It is possible that basal insulin co-administration compensated for the decline in b-cell function associated with longer type 2 diabetes duration in our study 2 . Indeed, it was shown that the addition of basal insulin significantly improved HbA1c in individuals inadequately controlled by liraglutide 7 . Second, the discrepancy between our study and the Wilbrink et al. study might be due to ethnic difference in type 2 diabetes pathophysiology. Type 2 diabetes in East Asian patients is characterized primarily by non-obesity and b-cell dysfunction, unlike type 2 diabetes in Caucasian patients, which is characterized by obesity and insulin resistance 8 . As impaired b-cell function is observed even in the early stage of type 2 diabetes in East Asian patients, type 2 diabetes duration might have less significance in predicting the HbA1c-lowering effects of liraglutide. Third, the discrepancy might be due to limited sample size (the Usui study on liraglutide/basal insulin, n = 38; the Usui study on liraglutide monotherapy or sulfonylurea combination, n = 88; and the Wilbrink et al. study, n = 69). Dependence of HbA1c-lowering effects of liraglutide/basal insulin combination on type 2 diabetes duration awaits further investigation by studies with larger sample sizes. Nevertheless, it is conceivable that liraglutide exerts greater HbA1c-lowering effects in the early stage of type 2 diabetes when ample b-cell function remains, and that addition of basal insulin or other antidiabetic drugs is required when b-cell function becomes substantially reduced. . Time-course curves were analyzed by mixedeffects models including group, time, and the interaction of group and time, and the P-values are shown. # P < 0.05 (vs patients with the median or above) by the Mann-Whitney U-test. The statistical analysis was carried out using SPSS Statistics 24 software (IBM Corp., Armonk, New York, USA). Each value represents the mean -standard error of the mean.
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